MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
AKRO Akero Therapeutics
- 29.340
- +0.940+3.31%
Close Dec 20 16:00 ET
- 29.340
- 0.0000.00%
Post 16:11 ET
2.05BMarket Cap-7.76P/E (TTM)
29.770High28.090Low1.56MVolume28.090Open28.400Pre Close45.63MTurnover2.84%Turnover RatioLossP/E (Static)69.80MShares37.00052wk High2.77P/B1.61BFloat Cap15.32052wk Low--Dividend TTM54.91MShs Float58.380Historical High--Div YieldTTM5.92%Amplitude7.520Historical Low29.249Avg Price1Lot Size
About Akero Therapeutics Company
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Company Profile
SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488
Websitehttp://www.akerotx.com
Company Executives
- Name
- Position
- Salary
- Dr. Andrew Cheng, M.D.,PhD
- President, Chief Executive Officer and Director
- 8.83M
- William R. White, J.D.
- Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
- 4.29M
- Dr. Timothy Rolph, D.Phil.
- Chief Scientific Officer
- 3.49M
- Catriona Yale
- Chief Development Officer
- 3.45M
- Dr. Jonathan Young, J.D.
- Executive Vice President, Chief Operating Officer and Secretary
- 3.44M
- Patrick Lamy
- Senior Vice President, Commercial Strategy
- --
- Mark T. Iwicki
- Chairman of the Board
- 606.06K
- Dr. Judy Chou, PhD
- Independent Director
- 571.06K
- Jane Pritchett Henderson
- Independent Director
- 586.06K
- Tomas J. Heyman
- Independent Director
- 581.06K
- Dr. Yuan Xu, PhD
- Independent Director
- 573.56K
- Dr. Seth L. Harrison, M.D.
- Independent Director
- 568.56K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 578.56K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.